Boehringer Ingelheim (BI) is expanding its global Pharmacometrics (PMx) group
in Biberach, Germany and Ridgefield, CT.
As a pharmacometrician with BI you act as a standing member in early and late
phase clinical drug development teams working closely together with experts in
the fields of medicine, clinical pharmacology, biomarker, clinical development,
and statistics. Pharmacometricians with the necessary experience and skill set
will have the opportunity to act as leader ("integrator") of those Early
Clinical Development Teams and Clinical Pharmacology and Biomarker Teams.
In addition to your role as a Project Pharmacometrician supporting one or
multiple projects, BI PMx offers two career development tracks (focus areas).
One of them focuses on strategic PMx support of clinical drug development
programs (i.e., model-informed drug discovery and development (MID3)). The
other one focuses on methodological and technical PMx work (i.e., performing
hands-on PMx analysis and developing and evaluating new PMx approaches and
methods).
Pharmacometricians are assigned to drug development projects approximately two
years before first-in-man clinical trials and support projects until successful
regulatory approval and beyond. BI PMx applies a question-based fit-for-purpose
approach to inform drug development with state-of-the-art PMx approaches that
include but are not limited to non-linear mixed effects models,
physiological-based pharmacokinetic models, and quantitative systems
pharmacology models.
Links USA:
http://d.rfer.us/BIRixl8Y3
http://d.rfer.us/BIREj08Y6
Link Germany:
https://tas-boehringer.taleo.net/careersection/global+template+career+section+28external29/jobdetail.ftl?job=174013
Tasks & Responsibilities
* Development and implementation of a model-informed drug discovery and
development (MID3) strategy for clinical drug development projects
* Planning, execution, and reporting of a wide variety of
pharmacometric analyses on a clinical trial and clinical drug development
project level
* Development and implementation of innovative pharmacometrics
approaches for supporting decision making in clinical drug development and
regulatory approval including but not limited to non-linear mixed effects
models, physiological-based pharmacokinetic models, and quantitative systems
pharmacology models
* Leading a team of pharmacometricians, Early Clinical Development
Teams, or Clinical Pharmacology and Biomarker Teams
Requirements
* PhD in Medicine, Pharmaceutics, Mathematics, Statistics, Systems
Pharmacology, Biology or equivalent area of focus with experience in
pharmacometrics in pre-clinical or clinical drug development (pharmaceutical
industry, academia or regulatory agency)
* Demonstrated competence with relevant data analysis software such as
NONMEM, Monolix, R, SAS, MATLAB, PBPK software, SimBiology.
* Proficient knowledge in clinical pharmacology and model informed drug
discovery and development
* For Senior Level Positions:
o Demonstrated consistent high quality MID3 contributions to clinical drug
development projects at different phases of clinical drug development
(strategic and operational)
o Successful track record of managing and developing direct reports
If you have questions, please do not hesitate to contact,
Recruiting Services, Germany, Biberach: Agnes Woyke, Email:
agnes.wo...@boehringer-ingelheim.com<mailto:agnes.wo...@boehringer-ingelheim.com>
Director Pharmacometrics, USA, Ridgefield: Benjamin Weber, Email:
benjamin.we...@boehringer-ingelheim.com<mailto:benjamin.we...@boehringer-ingelheim.com>
[esig-bi-logo-sm.png]<http://bit.ly/OJRIa8>
Benjamin Weber, PhD
Director, Pharmacometrics
Translational Medicine & Clinical Pharmacology
Boehringer Ingelheim Pharmaceuticals, Inc.
Ridgefield, Connecticut
P: 203-791-6240
benjamin.we...@boehringer-ingelheim.com<mailto:benjamin.we...@boehringer-ingelheim.com>
[icon-twitter.gif]<http://bit.ly/LO4IvZ>[icon-linkedin.gif]<http://linkd.in/LO4tAP>
[icon-youtube.gif] <http://bit.ly/PJCrqF>
CONFIDENTIALITY NOTICE: This e-mail message, including any attachments, is for
the sole use of the intended recipient(s) and may contain confidential and
privileged information. Any unauthorized review, use, disclosure of
distribution is prohibited. If you are not the intended recipient, please
contact sender by reply e-mail and destroy all copies of the original message.
